One of the major obstacles to successful chemotherapy of tumours is the development of drug resistance. This is a problem commonly associated with treatment using the classical folate antagonist methotrexate (MTX). MTX acts by inhibiting dihydrofolate reductase (DHFR), so depleting tetrahydrofolate, an essential cofactor in a number of onecarbon transfer reactions, including the biosynthesis of thymidylate required for DNA synthesis.
Mechanisms of acquired resistance to MTX include defective MTX transport (Sirotnak et al., 1981) , overproduction of DHFR (Alt et al., 1976 ) with a corresponding amplification of the DHFR gene (Alt et al., 1978) , altered DHFR with decreased affinity for MTX (Jackson & Niethammer, 1977) or increased activity (Dedhar et al., 1985) , and decreased ability to polyglutamylate MTX (Cowan & Jolivet, 1984) .
In the case of resistance due to altered transport of MTX, a number of approaches to overcoming resistance have been suggested. These include: (a) the use of antifolates that do not use the reduced folate/MTX transport system, such as the lipophilic drug trimetrexate (Kamen et al., 1984) ; (b) the use of high dose MTX with leucovorin rescue, as at high concentrations MTX is able to enter cells by passive diffusion (Hill et al., 1982) ; (c) the use of lipophilic esters of MTX (Rowsowsky et al., 1980) ; (d) attempting to bypass the MTX transport system by the use of MTX encapsulated in liposomes (Kosloski et al., 1978) , or conjugated to carriers such as albumin (Chu et al., 1981) and poly-(L)-lysine (Shen & Ryser, 1979) .
Another possible way of circumventing MTX-resistance due to transport deficiency could be the use of MTX conjugated to monoclonal antibodies, or antibody sub-units, which recognise tumour associated antigens. By allowing MTX to enter cells via an antibody-mediated route, the MTX transport system may be bypassed, and the transport defect avoided. This approach was investigated by deriving a number of MTX-resistant, transport-defective variant sublines of an osteogenic sarcoma cell line (791T), and assessing their sensitivities to monoclonal antibody-MTX conjugates.
The MTX-resistant sublines of the 791T line were grown in EMEM plus 10% NBCS, with added MTX at a concentration in which the subline was able to grow at the same rate as the parental cell line.
The MTX-resistant Chinese hamster ovary cell line M3000 was kindly provided by Dr A. Kinsella (Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester, UK), and was grown in Dulbeccos MEM with 10% foetal calf serum (Sera-lab Ltd., Sussex, UK). Cells were harvested with a mixture of 0.25% trypsin and 0.5% EDTA for use in in vitro assays.
Monoclonal antibodies
Monoclonal antibody 791T/36 is a murine IgG2b antibody, obtained from a hybridoma produced by fusing spleen cells from a mouse immunised against osteogenic sarcoma cell line 791T, with P3-NSl-Ag-4 mouse myeloma (Embleton et al., 1981) . This antibody was affinity purified from ascites fluid on a protein A column eluted with 3 M sodium thiocyanate. This antibody recognises a 72,000 molecular weight glycoprotein, termed gp72 (Price et al., 1983) . The 791T/48 antibody was also of the IgG2b subclass, and was raised against 791T cells, but it recognises an epitope on 791T cells separate from that detected by 791T/36 (Embleton et al., 1981) .
The 516 bispecific antibody which recognises both the 791T/36-defined gp72 antigen, and MTX conjugated to proteins including HSA was produced by fusing spleen cells from MTX immunised mice with 791T/36-producing hybridoma cells (Pimm et al., 1990) , and was provided by Dr M.V. Pimm of this department.
Chemicals
Methotrexate in alkaline saline (Cyanamid GB; Lederle Laboratories, Gosport, Hants, UK) was diluted to a stock solution of 1 mg ml-' in PBS. [3', 5', 7-3H] Conjugates MTX-HSA-791T/36 conjugates were prepared by the method of Garnett and Baldwin (1986) . Briefly, MTX was conjugated to HSA by reacting excess MTX and HSA with ethyl carbodiimide. This reaction produced some polymerised HSA-MTX which was removed by size exclusion chromatography. 791T/36 antibody was iodoacetylated by reacting the antibody with N-succinimidyl iodoacetate. Reduction of HSA-MTX with dithiothreitol activated the sulphydryl group and, after desalting, the reduced HSA-MTX was reacted with the iodoacetyl-substituted antibody.
Unreacted products were removed by gel filtration on Sephadex G-25 column. All conjugates were supplied by Dr M.C. Garnett, Cancer Research Campaign Laboratories, University of Nottingham.
Derivation of MTX-resistant sublines MTX-resistant sublines of the 791T line were derived by a method similar to that described by Varshavsky (1981 ). This assay has been shown to give results qualitatively equivalent to those obtained using clonogenic assays with MTX and MTX-conjugates (Garnett et al., 1983; Embleton et al., 1984; Embleton & Garnett, 1985) . (Roe et al., 1985) .
Transport studies The MTX-transport properties of the MTX-resistant variants were studied using a modified version of that described by Niethammer and Jackson (1975) . Cells growing in monolayer were harvested during logarithmic growth phase using trypsin/EDTA, and were pelleted and washed twice. 
Determination of DHFR levels
The method used was based on that of Kaufman et al. (1978) , and used fluoresceinated-MTX (Fluo-MTX) to quantitate DHFR. Fluo-MTX (Molecular Probes, Eugene, OR, USA) was diluted to 1 mM in 10 mM ammonium hydroxide and stored at -70C. Cells were maintained in monolayer culture in the absence of MTX for at least 6 days. MTXsensitive and resistant lines were then passaged into 60 mm tissue culture dishes, and allowed to grow in MTX-free medium. Prior to the attainment of confluence (late log phase) medium was removed from the cells and replaced with 2 ml of EMEM plus 10% NBCS containing 30 gM Fluo-MTX. In addition the medium contained 30 1M each of thymidine, glycine and hypoxanthine (Sigma) to protect the cells from the inhibitory effect of Fluo-MTX on DHFR (Kaufman et al., 1978) . To demonstrate that Fluo-MTX was binding to DHFR, M3000 cells were incubated in medium containing all of the supplements described above, but in addition 20 gM free MTX was also included to compete with Fluo-MTX for DHFR binding. Cells were incubated for 22 h at 37'C in 5% CO2 in the dark. Cells were then rinsed and incubated with 5 ml of EMEM plus 10% NBCS for 15 min at 37°C to allow efflux of unbound Fluo-MTX before they were gently harvested, washed and resuspended at about 2 x 106 cells ml ' in icecold HBSS plus 2% NBCS, and samples were maintained on ice prior to analysis for fluorescence at 488 nm using a FACS. For each determination at least 10,000 viable cells were run through the FACS. The mean linear fluorescence reading obtained was proportional to the DHFR level.
Results

Development of MTX-resistant 791 T sublines
The stepwise selection procedure described in 'Materials and methods' resulted in the establishment of four MTX-resistant sublines of the 791T cell line, designated R120, R160E, R250 and R500. These were named according to the maximum dose of MTX in ng ml-' in which the cells could be grown continuously (e.g. R120 was grown in a maximum dose of 120 ng ml-'). The R160E variant was grown in the absence of MTX and TPA as soon as continuous growth in 160 ng ml-' MTX was achieved in order to try to revert this line to MTX-sensitivity.
When tested for sensitivity to MTX in a [75Se]selenomethionine incorporation assay it was found that all four of the 791T variants were MTX-resistant relative to the parental 791T cell line by comparison of their IC50 values (Figure 1) Figure 2 . The MTX-resistant variants R120, R160E, R250 and R500 were all significantly transport deficient relative to parental cells but apart from the most resistant variant R500, showed no statistically significant difference from each other. The results shown are the mean of four separate determinations carried out on different days.
Levels of dihydrofolate reductase
The Fluo-MTX labelling method used to assess DHFR levels in the parental and MTX-resistant 791T sublines was based on the principle that Fluo-MTX binds stoichiometrically to DHFR such that, when cells are analysed using a FACS following incubation with Fluo-MTX, the level of fluorescence recorded should be proportional to the amount of DHFR enzyme present in the cells. Furthermore, Fluo-MTX is apparently transported into cells by passive diffusion and not via the reduced folate/MTX-transport system (Assaraf et al., 1989 (Gapski et al., 1975; Gaudray et al., 1986 ).
Investigation of extracts of the 791T lines by more conventional spectrophotometric assays never indicated increased DHFR concentrations. However, the extracts were found to be inhibitory towards exogenous purified DHFR, so biochemical assays were judged to be inappropriate for these cell lines (unpublished results, K.A.).
Cytotoxicity of MTX-HSA-79J T/36 conjugates Several MTX-HSA-791T/36 conjugates prepared by the method of Garnett and Baldwin (1986) against 791T parental and MTX-resistant cells is shown in Figure 4a through Figure 4e . The MHT6C1 conjugate was cytotoxic to 791T cells with an IC5o with respect to MTX of 16 ng ml-' (Figure 4a) , and was as cytotoxic to the variants R120, R160E and R250 as it was to parental cells, these variants giving ICo values of 8.6, 16.5 and 10.4 ng ml respectively (Figure 4a-Figure 4d ). The conjugate was, therefore, able to overcome the MTXresistance of the variants. These cytotoxicities were not due simply to higher expression of the 791T/36-defined gp72 antigen by the MTX-resistant sublines, since by indirect immunofluorescence techniques (see 'Materials and methods') the level of expression of this antigen by the sublines was high, but never higher than for parental 791T cells (Data not shown). The R500 line was about 10 times more sensitive to MHT6C1 than it was to free MTX with an ICo of 185 ng ml-' in terms of MTX (Figure 4e ), but it was not possible to overcome totally the resistance observed using the MTX-HSA-791T/36 conjugate. Several other similar conjugates resulted in comparable cytotoxicity against the 791T variants (data not shown). These conjugates were not cytotoxic to cells of the bladder carcinoma line T24, which had the same properties of growth rate and MTX-sensitivity as 791T cells, but which expressed less than 10% of the 791T/36-defined gp72 antigen level of 791T cells (data not shown). Similar results obtained by one of us (MJE) were published by Garnett and Baldwin (1986) .
Competitive effect offree antibody
In order to demonstrate formally that the cytotoxicity of the conjugates was mediated by antibody-antigen interaction, assays were carried out to determine the effect of competing free 791T/36 antibody on the cytotoxicity of MHT6C1 against R120 cells. For this, a fixed concentration of MHT6C1 or MTX was used which resulted in about 85% inhibition of ['5Se ]selenomethionine incorporation. These concentrations were 1 ig ml-' free MTX, and 32 ng ml-' with respect to MTX for the MHT6C1 conjugate. These doses were added to R120 cells in the presence of increasing concentrations of free 791T/36 antibody, or 791T/48 antibody (an antibody also raised against 791T cells, but which recognises a different epitope). Figure 5a shows that free 791T/36 antibody had no effect on the cytotoxicity of 1 isg ml-' MTX against R120 cells. However, this antibody progressively blocked the cytotoxic effect of MHT6C1 on R120 cells, giving complete inhibition at a ratio of about 25 free to 1 conjugated antibody molecule. It is important to note from Figure 5a that antibody 791T/36 alone did not affect the survival of the strongly antigen-positive R120 cell line, as shown previously for 791T cells .
The 791T/48 antibody had no effect on cell survival, or on the cytotoxicity against R120 of either MTX or MHT6C1 conjugate ( Figure Sb) .
These data suggest that the cytotoxic effect of MTX-HSA-791T/36 conjugates, such as MHT6C1, was via an antibodymediated mechanism of drug entry into the cell.
Parallel studies concerning the mode of action of these MTX-HSA-791T/36 conjugates (data not shown) have given further support to this proposal. Cocarboxylase (or thiamine pyrophosphate, Sigma), a potent inhibitor of the reduced folate/MTX transport system (Henderson & Zevely, 1983) , had no effect on the cytotoxicity of the MHT6C1 conjugate against R120 cells, indicating that none of the cytotoxicity observed was due to free drug released from the conjugate extracellularly. Furthermore, by use of agents able to inhibit lysosomal protein degradation (ammonium chloride (Ohkuma & Poole, 1978) and leupeptin (Seglen et al., 1979) ), it was shown that, once internalised, the MTX-HSA-791T/36 conjugates require lysosomal degradation to release free MTX in order to exert their cytotoxic effect, also shown previously for such conjugates (Garnett et al., 1985) . problems (Pimm et al., 1987) (Thorpe & Ross, 1982) , radionuclides (Buchegger et al., 1988) , enzymes (Bagshawe, 1987) , and conventional cytotoxic drugs, such as vindesine , methotrexate (Embleton & Garnett, 1985) , and daunomycin (Gallego et al., 1984 (Embleton & Garnett, 1985) . A large proportion of this work has centred on the use of the anti-folate drug methotrexate (MTX) and the monoclonal antibody 791T/36, which was raised against the human osteogenic sarcoma cell line, 791T (Embleton et al., 1981) , and recognises a 72,000 molecular weight glycoprotein (gp72) on the cell surface (Price et al., 1983 tance was overcome partially, suggesting that mechanisms of resistance other than transport deficiency may have been involved. Investigation of the mode of action of these conjugates, using the R120 MTX-resistant 791T variant as an example, showed that they required antibody binding for cytotoxicity, suggesting that the conjugates were able to overcome resistance in the transport deficient cells by allowing drug to enter via an antibody-mediated mechanism, so by-passing the defective MTX carrier.
These studies suggested that in vitro it was possible to overcome totally or partially the resistance to MTX of variants of the cell line 791T using monoclonal antibody-HSA-MTX conjugates. However, antibody-carrier-drug conjugates of this type have poor properties of biodistribution in vivo (Pimm et al., 1987) , and poor tumour localisation and penetration due mainly to their larger size, and therefore the in vitro ability of these conjugates to overcome totally MTXtransport deficiency may not be realised in vivo.
An alternative approach was tested, using the 516 bispecific antibody (which recognises both MTX and 791T/36 antibody (Pimm et al., 1990) , to target highly substituted HSA-MTX to the MTX-resistant 791T subline R120; by pre-targeting the antibody to the tumour site prior to the administration of HSA-MTX some of the in vivo biodistribution problems associated with the indirect conjugates may be avoided. It was found that in vitro the 516 antibody was able to augment the cytotoxicity of HSA-MTX to R120 cells as efficiently as for parental 791T cells, but it was not possible to overcome totally the resistance of this line by this approach. However, this could have been due to the relatively low affinity of the 516 antibody (Pimm et al., 1990) , and if a more suitable antibody could be produced perhaps greater cytotoxicity could be achieved.
The studies described here have shown that antibodytargeting approaches to chemotherapy could totally or partially overcome the MTX-transport deficiency of the 791T sublines in vitro. However it must be stressed that these investigations have demonstrated the feasibility of the principle, and do not claim to have clinical applications using the ragents described. However, it is hoped that if more suitable immunologically targeted reagents could be developed this approach may have some therapeutic potential in tackling the problem of acquired drug resistance by tumour cells during cancer chemotherapy due to defective drug transport mechanisms.
